| 000 | 01810 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518013435.0 | ||
| 264 | 0 | _c20190523 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1600-0560 | ||
| 024 | 7 |
_a10.1111/cup.13401 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aParekh, Vishwas | |
| 245 | 0 | 0 |
_aNRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. _h[electronic resource] |
| 260 |
_bJournal of cutaneous pathology _cMar 2019 |
||
| 300 |
_a190-194 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGTP Phosphohydrolases _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 |
_aMembrane Proteins _xgenetics |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aNeoplasms, Second Primary _xchemically induced |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins B-raf _xgenetics |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aSkin Neoplasms _xchemically induced |
| 650 | 0 | 4 |
_aVemurafenib _xadverse effects |
| 650 | 0 | 4 | _aMelanoma, Cutaneous Malignant |
| 700 | 1 | _aSobanko, Joseph | |
| 700 | 1 | _aMiller, Christopher J | |
| 700 | 1 | _aKarakousis, Giorgos | |
| 700 | 1 | _aXu, Wei | |
| 700 | 1 | _aLetrero, Richard | |
| 700 | 1 | _aElenitsas, Rosalie | |
| 700 | 1 | _aXu, Xiaowei | |
| 700 | 1 | _aElder, David E | |
| 700 | 1 | _aAmaravadi, Ravi | |
| 700 | 1 | _aSchuchter, Lynn M | |
| 700 | 1 | _aNathanson, Katherine L | |
| 700 | 1 | _aWilson, Melissa A | |
| 700 | 1 | _aChu, Emily Y | |
| 773 | 0 |
_tJournal of cutaneous pathology _gvol. 46 _gno. 3 _gp. 190-194 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/cup.13401 _zAvailable from publisher's website |
| 999 |
_c29165578 _d29165578 |
||